Sinotherapeutics Inc. (SHA:688247)

Sinotherapeutics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	209.19	225.79	641.79	763.15	511.66	434.17
Short-Term Investments	-	-	107.21	44.09	-	-
Trading Asset Securities	534.11	507.74	-	-	-	-
Cash & Short-Term Investments	743.3	733.53	749	807.23	511.66	434.17
Cash Growth	-0.64%	-2.07%	-7.21%	57.77%	17.85%	68.23%
Accounts Receivable	93.46	110.97	78.47	71.27	44.09	35.84
Other Receivables	1	0.3	0.57	-	-	10.54
Receivables	94.45	111.27	79.04	71.27	44.09	46.38
Inventory	100.71	102.42	84.61	29.38	40.43	41.81
Other Current Assets	19.57	29.1	39.36	45.83	22.66	23.64
Total Current Assets	958.04	976.32	952.01	953.71	618.83	546
Property, Plant & Equipment	359.05	344.34	271.41	255.92	115.09	105.72
Long-Term Investments	65.14	64.42	64.2	49.1	69.99	7.86
Goodwill	18.39	18.39	18.39	18.39	-	-
Other Intangible Assets	18.26	21.65	27.59	32.47	41.16	51.58
Long-Term Deferred Tax Assets	18.76	19.33	14.29	16.45	16.08	14.44
Long-Term Deferred Charges	0.68	0.92	1.21	1.99	3.15	3.81
Other Long-Term Assets	5.1	7.94	12.54	4.3	1.5	9.39
Total Assets	1,443	1,453	1,362	1,332	865.81	738.8
Accounts Payable	15.4	16.75	13.34	8.42	8.01	5.39
Accrued Expenses	9.56	26.49	14.69	11.58	14.19	32.15
Current Portion of Leases	0.04	0.01	0.06	0.32	0.78	-
Current Income Taxes Payable	1.72	6.97	1.28	0.45	7.85	-
Current Unearned Revenue	30.22	30.44	48.01	56.8	46.78	95.51
Other Current Liabilities	15.24	22.54	13.33	12.47	11.92	9.48
Total Current Liabilities	72.17	103.19	90.72	90.05	89.52	142.54
Long-Term Leases	-	-	0.02	1.2	3.66	-
Long-Term Unearned Revenue	67.61	74.72	58.09	61.12	64.62	30.93
Long-Term Deferred Tax Liabilities	2.32	2.39	2.53	2.68	2.82	2.96
Total Liabilities	142.1	180.3	151.36	155.05	160.62	176.42
Common Stock	453.34	453.34	453.34	453.34	408	408
Additional Paid-In Capital	512.9	513.57	512.89	512.89	179.23	171.29
Retained Earnings	371.19	342.22	244.16	211.19	118.26	-16.66
Treasury Stock	-36.13	-36.13	-	-	-	-
Comprehensive Income & Other	0	-	-0.13	-0.15	-0.31	-0.26
Shareholders' Equity	1,301	1,273	1,210	1,177	705.19	562.38
Total Liabilities & Equity	1,443	1,453	1,362	1,332	865.81	738.8
Total Debt	0.04	0.01	0.09	1.52	4.44	-
Net Cash (Debt)	743.27	733.53	748.92	805.71	507.22	434.17
Net Cash Growth	-0.64%	-2.05%	-7.05%	58.85%	16.82%	68.23%
Net Cash Per Share	1.62	1.61	1.59	1.91	1.24	1.06
Filing Date Shares Outstanding	449	449	449.15	453.34	408	408
Total Common Shares Outstanding	449	449	453.34	453.34	408	408
Working Capital	885.87	873.13	861.29	863.66	529.31	403.47
Book Value Per Share	2.90	2.84	2.67	2.60	1.73	1.38
Tangible Book Value	1,265	1,233	1,164	1,126	664.02	510.79
Tangible Book Value Per Share	2.82	2.75	2.57	2.48	1.63	1.25
Buildings	247.02	216.23	211.68	54.29	52.41	45.57
Machinery	199.88	183.49	160.89	145.6	135.93	117.73
Construction In Progress	61.11	80.75	15.35	153.61	4.68	9.32

Source: S&P Global Market Intelligence. Standard template. Financial Sources.